摘要
目的探究吉非替尼对肺癌患者Ki-67及p53表达及预后影响。方法选取2007年10月~2014年6月浙江省肿瘤医院病理科收治的肺癌患91例,46例口服吉非替尼治疗的归入治疗组,45例采用紫杉醇联合顺铂化疗方案治疗的归入对照组。2组患者予以常规治疗以及个体化对症治疗后,均有支气管镜活检、粗针穿刺、胸水细胞包埋或手术样本,进行免疫组化染色后对比分析2组Ki-67及p53阳性表达率、p U值及复发率。结果与对照组相比,治疗组患者的Ki-67及p53阳性表达率较低（P〈0.05）,阴性表达率较高（P〈0.05）,Ki-67及p53p U值较低（P〈0.05）,复发率较低（P〈0.05）。结论吉非替尼对肺癌患者Ki-67及p53的基因表达具有调控作用,抑制癌细胞的侵润和转移,改善临床疗效与预后。
Objective To investigate the effect of Ki-67 and p53 expression and prognosis in patients with lung cancer by Iressa. Methods 91 cases of lung cancer in Cancer Hospital of Zhejiang Province from October 2007 to June 2014 were randomly divided into 45 cases in control group and46 cases in treatment group. Two groups of patients were treated with conventional therapy and individual symptomatic treatment; The treatment group was treated with oral administration of Iressa,two groups of patients were selected according to the condition of each patient lobe or lung resection,chemotherapy regimen of paclitaxel combined with cisplatin. After the end of treatment,two groups were compared,the positive expression rate of p U,Ki-67,p53 and the recurrence rate were compared. Results Compared with control group,the positive expression rate of Ki-67 and p53 in treatment group was lower（ P〈0. 05）,the negative expression rate was higher（ P〈0. 05）,Ki-67 and p53 p U were lower（ P〈0. 05）,and the recurrence rate was lower（ P〈0. 05）. Conclusion Iressa has regulation function in patients with lung cancer by the gene expression of and Ki-67 and p53,which can inhibit the invasion and metastasis of cancer cells,improve the clinical efficacy and prognosis.
出处
《中国生化药物杂志》
CAS
2016年第3期82-84,共3页
Chinese Journal of Biochemical Pharmaceutics
